The crucial drugs can have unintended consequences. Innovative therapies could shield the microbiome from their effects.

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics ... has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20.

Shares of PLRX stock opened at $2.61 on Monday. Pliant Therapeutics has a fifty-two week low of $2.60 and a fifty-two week high of $18.00. The firm’s 50 day moving average price is $12.42 and ...

NASDAQ AXSM opened at $106.46 on Wednesday. Axsome Therapeutics has a one year low of $64.11 and a one year high of $111.51. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 ...

NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ ... has received authorization from Health Canada to extend its U.S. clinical trial for Decoy20 to Canadian sites. This move aims to accelerate ...

PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary ...

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ ...

NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company with a market capitalization of approximately $13 million, has received authorization from Health Canada to ...

PROVIDENCE, R.I. (WPRI) — Rhode Island’s first pallet shelter community officially opened Tuesday morning. A grand opening ceremony was held at ECHO Village, located on Victor Street, where ...

Indaptus Therapeutics, Inc. has received Clinical Trial Authorization from Health Canada to expand its U.S. clinical trial of Decoy20, a treatment for cancer and viral infections, into Canadian sites.